GlassScriptPhysician profile
Abdul Nuristani
NPI 1245467273
$3,271.49
in general payments reported to CMS, 2019-2025
22 companies · $732 in 2025
The $732 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.23 · 2021: $375 · 2022: $866 · 2023: $460 · 2024: $826 · 2025: $732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,018.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,018.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $582.48 | 2022-2025 | Tavneos, Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $472.33 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $359.58 | 2021-2024 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $285.15 | 2021-2024 | Farxiga, Lokelma |
| Aurinia Pharma U.S., INC. | $213.93 | 2022-2024 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $201.39 | 2023-2025 | Jardiance |
| Travere Therapeutics, INC. | $200.24 | 2022-2025 | |
| Akebia Therapeutics INC | $178.63 | 2025 | Vafseo |
| Vifor Pharma, INC. | $170.97 | 2021-2025 | Veltassa |
| Alexion Pharmaceuticals, INC. | $124.99 | 2023 | |
| Baxter Healthcare | $95.76 | 2022 | |
| Apellis Pharmaceuticals, INC. | $91.83 | 2025 | |
| Ardelyx, INC. | $54.77 | 2024-2025 | Ibsrela |
| Mallinckrodt Hospital Products INC. | $51.49 | 2024 | Acthar |
| Scpharmaceuticals INC. | $36.14 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $30.59 | 2025 | |
| Abbvie INC. | $26.93 | 2024 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $22.48 | 2022 | |
| Novo Nordisk INC | $21.83 | 2023 | Ozempic, Rybelsus |
| Fresenius USA Marketing, INC. | $19.60 | 2024 | Velphoro |
| Glaxosmithkline, LLC. | $18.15 | 2022 | |
| Sanofi-Aventis U.S. LLC | $12.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdul Nuristani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.